Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKN63V
|
|||
| Drug Name |
Pelacarsen
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 3 | [1] | |
| Hyperlipoproteinemia [ICD-11: 5C80; ICD-10: E78.4, E78.5] | Phase 3 | [2] | ||
| Company |
Ionis; Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein A messenger RNA (LPA mRNA) | Target Info | Inhibitor | [3] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Plasminogen activating cascade | |||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | LDL-mediated lipid transport | |||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04023552) A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05900141) A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.. U.S.National Institutes of Health. | |||
| REF 3 | Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.